Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
B 149.06 -2.10% -3.19
ABBV closed down 2.1 percent on Friday, September 29, 2023, on 89 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Cup with Handle Other 0.00%
Multiple of Ten Bearish Other 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -2.10%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.10%
Cup with Handle Other -2.10%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 10 hours ago
Fell Below 50 DMA about 10 hours ago
50 DMA Support about 11 hours ago
60 Minute Opening Range Breakdown about 11 hours ago
Down 1 ATR about 11 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


AbbVie Inc. Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Pharmaceutical Plastic Autoimmune Disease Infection Psoriasis Regenerative Medicine Ulcerative Colitis Anemia Depressive Disorder Hepatitis C Atopic Dermatitis Crohn's Disease Hematological Malignancies Hepatitis C Virus Constipation Irritable Bowel Syndrome Migraine Immunosuppressants Psoriatic Arthritis Blood Cancers Skincare Products Treatment Of Migraine Adalimumab Combination Drugs Endometriosis Eye Care Products Genotype Spondylitis Uterine Fibroid Advanced Prostate Cancer Chronic Idiopathic Constipation Hypothyroidism Ocular Hypertension Severe Plaque Psoriasis

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 164.3777
52 Week Low 129.5242
Average Volume 4,249,508
200-Day Moving Average 147.75
50-Day Moving Average 149.55
20-Day Moving Average 151.16
10-Day Moving Average 153.02
Average True Range 2.39
RSI (14) 44.44
ADX 20.09
+DI 15.37
-DI 23.36
Chandelier Exit (Long, 3 ATRs) 147.72
Chandelier Exit (Short, 3 ATRs) 150.90
Upper Bollinger Bands 156.57
Lower Bollinger Band 145.76
Percent B (%b) 0.31
BandWidth 7.15
MACD Line 1.15
MACD Signal Line 1.48
MACD Histogram -0.3334
Fundamentals Value
Market Cap 263.16 Billion
Num Shares 1.77 Billion
EPS 4.57
Price-to-Earnings (P/E) Ratio 32.60
Price-to-Sales 4.13
Price-to-Book 12.13
PEG Ratio 1.28
Dividend 5.20
Dividend Yield 3.49%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 154.94
Resistance 3 (R3) 155.52 154.13 153.96
Resistance 2 (R2) 154.13 152.64 153.85 153.63
Resistance 1 (R1) 151.60 151.71 150.91 151.02 153.31
Pivot Point 150.21 150.21 149.87 149.93 150.21
Support 1 (S1) 147.68 148.72 146.99 147.10 144.81
Support 2 (S2) 146.29 147.79 146.01 144.49
Support 3 (S3) 143.76 146.29 144.16
Support 4 (S4) 143.18